| خلاصه مقاله | • Background: Signal transduction and transcription activator 3 (STAT3) as an oncogene plays a role in the initiation and progression of various cancers. Accumulated studies show that STAT3 is highly expressed in metastatic carcinomas such as lung cancer. We conducted a systematic review to identify the relationship between STAT3 expression and lung cancer.
• Methods: We searched the keywords STAT3 and lung cancer from several databases including PubMed, Scopus, and Google Scholar from 2016 to 2024. The inclusion criteria included studies conducted in vitro, in vivo, and in clinical conditions that evaluated the involvement of STAT3 in lung cancer. Data extraction investigated the therapeutic implications of STAT3 and the pathways by which STAT3 affects lung cancer.
• Results: The findings of 16 reviewed articles show that STAT3 activation in lung cancer tissues and cell lines is associated with increased tumor cell proliferation, invasion, survival, and resistance to chemotherapy. Therapeutic Interventions Such as RNAi and small molecule inhibitors targeting STAT3 have shown encouraging results in preclinical studies, but their efficacy has not yet been fully confirmed in clinical settings.
• Conclusion: In most lung cancers, high STAT3 expression is associated with a lower survival rate. Preclinical studies showed significant effectiveness of drugs targeting the STAT3 signaling pathway in treating lung cancer. Therefore, this pathway is a potential therapeutic target in lung cancer. |